Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44380 clinical trials with a EudraCT protocol, of which 7392 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (44,380)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

44,380 result(s) found. Displaying page 2,110 of 2,219.

EudraCT Number: 2017-000421-13	Sponsor Protocol Number: 1913	Start Date*: 2017-07-27
Sponsor Name:Erasmus MC
Full Title: Newborns with Congenital Diaphragmatic hernia: inhaled Nitric Oxide versus intravenous Sildenafil: an international randomized controlled trial
Medical condition: Congenital diaphragmatic hernia with pulmonary hypertension
Disease:
Population Age: Preterm newborn infants, Newborns, Under 18		Gender: Male, Female
Trial protocol: NL (Completed) NO (Prematurely Ended) AT (Prematurely Ended) SE (Ongoing) BE (Completed) IT (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2011-000440-22

Sponsor Protocol Number: EURO-SKI01

Start Date*: 2012-04-11

Sponsor Name:University of Heidelberg

Full Title: MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI

Medical condition: Patients with chronic myeloid leukemia with complete molecular response can stop tyrosine kinase inhibitors under close monitoring

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.0	100000004864	10009016	Chronic myeloid leukemia in remission	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Ongoing) FI (Completed) CZ (Completed) NL (Ongoing) NO (Completed) PT (Completed) AT (Prematurely Ended) ES (Ongoing) DK (Completed)

Trial results: (No results available)

EudraCT Number: 2019-002348-26	Sponsor Protocol Number: HUS-PERFECT	Start Date*: 2020-02-18
Sponsor Name:Helsinki University Hospital
Full Title: Role of delay and antibiotics on PERForation rate while waiting appendECTomy – Randomized non-inferiority trial (PERFECT)
Medical condition: Acute appendicitis
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FI (Completed) NO (Completed)
Trial results: (No results available)

EudraCT Number: 2019-002895-14

Sponsor Protocol Number: APD334-202

Start Date*: 2020-02-13

Sponsor Name:Arena Pharmaceuticals Inc.

Full Title: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects with Moderately to S...

Medical condition: Crohn's Disease

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10017947 - Gastrointestinal disorders	10011401	Crohn's disease	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: LT (Prematurely Ended) NO (Completed) GB (Prematurely Ended) GR (Prematurely Ended) PT (Prematurely Ended) FR (Completed) CZ (Prematurely Ended) SK (Prematurely Ended) NL (Completed) BG (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) IT (Completed)

Trial results: View results

EudraCT Number: 2012-004321-25

Sponsor Protocol Number: NordDutchCML009

Start Date*: 2013-04-03

Sponsor Name:VU University Medical Center

Full Title: A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon α2b in patients with suboptimal molecular response or stable detectable molecular residual disease af...

Medical condition: Chronic myeloid leukemia in chronic phase and ≥ 2 years on Imatinib treatment with suboptimal molecular response (BCR-ABL level above 0.01% IS).

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.0	100000004864	10009700	CML	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Prematurely Ended) SE (Completed) NO (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2020-003906-29

Sponsor Protocol Number: CLCZ696G2301E1

Start Date*: 2021-02-08

Sponsor Name:Novartis Pharma AG

Full Title: A multicenter study to evaluate the long-term safety and tolerability of open-label LCZ696 in patients with acute myocardial infarction who previously participated in CLCZ696G2301 (PARADISE-MI)

Medical condition: Left ventricular dysfunction following an acute myocardial infarction and/or pulmonary congestion requiring intravenous treatment

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10007541 - Cardiac disorders	10000891	Acute myocardial infarction	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Prematurely Ended) GR (Prematurely Ended) NO (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended)

Trial results: View results

EudraCT Number: 2005-005494-29	Sponsor Protocol Number: 1603	Start Date*: Information not available in EudraCT
Sponsor Name:Ullevål University Hospital
Full Title: Rifampin combination therapy versus monotherapy in early staphylococcal infections after total hip and knee arthroplasty
Medical condition: Joint prosthesis infection after total hip and knee arthroplasty.
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: NO (Completed)
Trial results: (No results available)

EudraCT Number: 2019-003501-10	Sponsor Protocol Number: MBWtodetectPEXinCF	Start Date*: 2020-04-08
Sponsor Name:Västra Götalandsregionen
Full Title: Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a multicenter randomized controlled study.
Medical condition: Cystic fibrosis
Disease:
Population Age: Children, Adolescents, Under 18		Gender: Male, Female
Trial protocol: SE (Ongoing) DK (Prematurely Ended) NO (Completed)
Trial results: View results

EudraCT Number: 2006-001367-36

Sponsor Protocol Number: DoxP-01/2006

Start Date*: 2006-12-05

Sponsor Name:Prof. Dr. Peter Eickholz

Full Title: Benefit of adjunctive systemic postsurgical doxycycline in regenerative periodontal surgery

Medical condition: Periodontitis is an opportunistic infectious disease that destroys the periodontal attachment and bone. Bacterial plaque (biofilm) on the teeth adjacent to the gingiva is the necessary cause gingiv...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10034539	Periodontitis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2015-001703-32

Sponsor Protocol Number: VASE

Start Date*: 2015-11-09

Sponsor Name:Cliniques Universitaires Saint-Luc (CUSL)

Full Title: Phase III multicentric study evaluating the efficacy and safety of sirolimus in Vascular Anomalies that are refractory to standard care

Medical condition: Complex vascular anomalies causing debilitating functional and esthetic impairment that are resistant to standard care

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.1	100000004850	10047047	Vascular anomalies congenital NEC	HLT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) FR (Completed) DE (Ongoing) NO (Completed)

Trial results: (No results available)

EudraCT Number: 2011-004257-29

Sponsor Protocol Number: 11-12

Start Date*: 2013-05-03

Sponsor Name: All Ireland Cooperative Oncology Research Group ( ICORG)

Full Title: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma

Medical condition: High-risk resected melanoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	100000004865	10025651	Malignant melanoma excision	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IE (Completed) Outside EU/EEA

Trial results: View results

EudraCT Number: 2013-000726-66

Sponsor Protocol Number: GETNE1206

Start Date*: 2014-10-08

Sponsor Name:Grupo Español de Tumores Neuroendocrinos (GETNE)

Full Title: Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by ...

Medical condition: advanced progressive pNETs

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10067517	Pancreatic neuroendocrine tumour	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10068909	Pancreatic neuroendocrine tumour metastatic	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Completed) DE (Completed) IT (Completed) ES (Completed) DK (Completed) NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA)

Trial results: View results

EudraCT Number: 2018-001059-12

Sponsor Protocol Number: 15-HMedIdeS-09

Start Date*: 2019-05-29

Sponsor Name:Hansa Biopharma AB

Full Title: An open-label, single arm, multi-centre, phase II study investigating safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of imlifidase (IdeS) in patients with Guillain-Barré Synd...

Medical condition: Guillain-Barré Syndrome (GBS)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004852	10018766	Guillain Barre syndrome	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed)

Trial results: View results

EudraCT Number: 2019-003208-11

Sponsor Protocol Number: CRF002

Start Date*: 2020-03-04

Sponsor Name:Chelsea and Westminster Hospital NHS Foundation Trust

Full Title: Efficacy of BIC/F/TAF versus standard of care in the treatment of new HIV infection diagnoses in the context of 'test and treat'

Medical condition: Human Immunodeficiency Virus (HIV) infection

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004862	10020441	Human immunodeficiency virus infection, unspecified	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA)

Trial results: View results

EudraCT Number: 2020-004777-49

Sponsor Protocol Number: 20-HMedIdeS-18

Start Date*: 2020-12-17

Sponsor Name:Hansa Biopharma

Full Title: A prospective, observational long-term follow-up trial of kidney transplant patients treated with imlifidase or plasma exchange after an active/chronic active Antibody-Mediated Rejection episode

Medical condition: Antibody-mediated rejection in kidney transplant patients

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10021428 - Immune system disorders	10023439	Kidney transplant rejection	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed) AT (Completed) DE (Completed)

Trial results: View results

EudraCT Number: 2019-003334-16

Sponsor Protocol Number: BUS-5/UCA

Start Date*: 2020-06-26

Sponsor Name:Dr. Falk Pharma GmbH

Full Title: Randomised, double-blind, placebo-controlled, multicentre study to compare the efficacy and safety of novel 4 mg budesonide suppository in combination with oral mesalazine versus oral mesalazine mo...

Medical condition: acute ulcerative colitis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.1	100000004856	10066678	Acute ulcerative colitis	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Completed) BG (Completed) LV (Completed)

Trial results: View results

EudraCT Number: 2008-004551-30

Sponsor Protocol Number: ICORG08-02Nilotinib

Start Date*: 2008-10-31

Sponsor Name:ICORG

Full Title: A phase II multi-center, open-label, study of Nilotinib at a dose of 300mg twice daily in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in ...

Medical condition: Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	100000004864	10009012	Chronic myelogenous leukemia	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IE (Completed) GB (Completed) DE (Completed)

Trial results: View results

EudraCT Number: 2015-004936-36

Sponsor Protocol Number: CLL13

Start Date*: 2016-11-08

Sponsor Name:University of Cologne

Full Title: A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus ve-netoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) ve...

Medical condition: fit patients with previously untreated CLL without del(17p) or TP53 mutation

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	100000004864	10008976	Chronic lymphocytic leukemia	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Completed) DK (Completed) DE (Completed) AT (Completed) FI (Completed) BE (Completed) IE (Completed)

Trial results: View results

EudraCT Number: 2015-005537-50

Sponsor Protocol Number: 15/BWH/P061

Start Date*: Information not available in EudraCT

Sponsor Name:Birmingham Women's Hospital

Full Title: High Or Low Dose Syntocinon® for delay in labour: the HOLDS trial

Medical condition: Approximately a third of women become delayed in their first labours and are given intravenous oxytocin in an attempt to increase their uterine contractions, increase spontaneous vaginal birth and ...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10036585 - Pregnancy, puerperium and perinatal conditions	10000153	Abnormal labour	PT

Population Age: Adolescents, Under 18, Adults

Gender: Female

Trial protocol: GB (GB - no longer in EU/EEA)

Trial results: View results

EudraCT Number: 2021-001309-60

Sponsor Protocol Number: MK4280A-007

Start Date*: 2021-10-08

Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Full Title: A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer

Medical condition: Metastatic Colorectal Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	100000004864	10052362	Metastatic colorectal cancer	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Temporarily Halted) DE (Completed) CZ (Completed) NO (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned)

Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Wed Feb 11 06:38:54 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA